The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Unguryan V.M.

Kostroma Oncology Dispensary

Kazantsev A.N.

Kostroma Regional Oncology Dispensary;
B.V. Petrovsky Russian Scientific Center of Surgery;
Kostroma Regional Clinical Hospital named after E.I. Korolev

Abduragimov A.M.

I.I. Mechnikov North-Western State Medical University

Belov Yu.V.

B.V. Petrovsky Russian Scientific Center of Surgery;
I.M. Sechenov First Moscow State Medical University

Modern treatment methods for patients with liver metastases from uveal melanoma

Authors:

Unguryan V.M., Kazantsev A.N., Abduragimov A.M., Belov Yu.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(2): 74‑84

DOI: 10.17116/onkolog20241302174

Read: 1555 times

Download PDF (RU)
Contact the author
Table of contents

MODERN TREATMENT METHODS FOR PATIENTS WITH LIVER METASTASES FROM UVEAL MELANOMA
MODERN TREATMENT METHODS FOR PATIENTS WITH LIVER METASTASES FROM UVEAL MELANOMA

To cite this article:

Unguryan VM, Kazantsev AN, Abduragimov AM, Belov YuV. Modern treatment methods for patients with liver metastases from uveal melanoma. P.A. Herzen Journal of Oncology. 2024;13(2):74‑84. (In Russ.)
https://doi.org/10.17116/onkolog20241302174

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
Clinical significance of gene­tic muta­tions in epithelial tumors of the thymus. P.A. Herzen Journal of Onco­logy. 2025;(2):70-75
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Meta­stasis of thyroid cancer to retroperitoneal lymph nodes and breast. P.A. Herzen Journal of Onco­logy. 2025;(4):82-85
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99
Possibilities of using bacterial lysa­tes in the treatment and prevention of upper respiratory tract infe­ctious diseases. Russian Rhinology. 2024;(4):314-322
New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38
A clinical case of fami­lial alopecia areata in combination with immune pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):304-312
Application of T-cells with chimeric anti­gen rece­ptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medi­cine. 2025;(7):106-110
Abstract:

Uveal melanoma is a rare malignant neoplasm originating from the uveal tract of the eye. The liver is the most common site of metastasis, occurring in 70—90% of cases and becoming the sole site of metastasis in approximately 50% of observations. This literature review presents modern methods for treating liver metastases from uveal melanoma: immunotherapy, targeted therapy, oncolytic adenovirus therapy, chemoembolization, transarterial chemoembolization, drug-eluting bead therapy, immunoembolization, radioembolization, thermal ablation, isolated hepatic perfusion. The conclusion is drawn about the highest efficacy, safety, and availability of isolated hepatic perfusion compared to other treatment methods.

Keywords:

immunotherapy
targeted therapy
oncolytic adenovirus therapy
chemoembolization
transarterial chemoembolization
drug-eluting bead therapy
immunoembolization
radioembolization
thermal ablation
isolated hepatic perfusion

Authors:

Unguryan V.M.

Kostroma Oncology Dispensary

Kazantsev A.N.

Kostroma Regional Oncology Dispensary;
B.V. Petrovsky Russian Scientific Center of Surgery;
Kostroma Regional Clinical Hospital named after E.I. Korolev

Abduragimov A.M.

I.I. Mechnikov North-Western State Medical University

Belov Yu.V.

B.V. Petrovsky Russian Scientific Center of Surgery;
I.M. Sechenov First Moscow State Medical University

Received:

18.05.2023

Accepted:

26.07.2023

Close metadata

References:

  1. Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, Pfeffer U. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109-140.  https://doi.org/10.1007/s10555-017-9663-3
  2. Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973—2013). Ocul Oncol Pathol. 2018;4(3):145-151.  https://doi.org/10.1159/000480640
  3. Zherko IYu, Naumenko LV, Zhilyaeva EP, Evmenenko AA, Korsik VYu, Portyanko AS. Treatment outcomes in patients with metastatic uveal melanoma: a retrospective monocenter study. Issues of Oncology. 2022;68(2):224-231. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-2-224-231
  4. Wang Q, He J, Qi Y, Ye Y, Ye J, Zhou M. Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma. Biomaterials. 2024;305:122458. https://doi.org/10.1016/j.biomaterials.2023.122458
  5. Kaprin AD, Ivanov SA, Unguryan VM, Petrov LO, Pobedintseva YuA, Falaleeva NA, Filimonov EV, Kruglov EA. Current possibilities of using isolated liver chemoperfusion in the treatment of metastatic uveal melanoma. Palliative Medicine and Rehabilitation. 2021;(4):5-10. (In Russ.).
  6. Nguyen JQN, Drabarek W, Vaarwater J, Yavuzyigitoglu S, Verdijk RM, Paridaens D, Naus NC, de Klein A, Brosens E, Kiliç E; Rotterdam Ocular Melanoma Study group. 8q Gain Has No Additional Predictive Value in SF3B1MUT Uveal Melanoma but Is Predictive for a Worse Prognosis in Patients with BAP1MUT Uveal Melanoma. Ophthalmol Sci. 2023;4(2):100413. https://doi.org/10.1016/j.xops.2023.100413
  7. Sinyavskii OA, Troyanovskii RL, Ivanov PI, Tibilov AV, Golovin AS, Solonina SN, Mednikov SN, Astapenko AM, Toyalinova TM, Rodina LN, Zubatkina IS. Five-year experience of resections of uveal melanomas after stereotactic radiosurgery using a gamma knife. Modern Technologies in Ophthalmology. 2018;(1):316-319. (In Russ.).
  8. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241-257.  https://doi.org/10.1038/eye.2016.275
  9. Grishina EE, Stepanova EA, Bogatyrev AM. Diagnosis of metastatic uveal melanoma. What has changed in 10 years? Almanac of Clinical Medicine. 2019;47(8):712-720. (In Russ.). https://doi.org/10.18786/2072-0505-2019-47-050
  10. Saakyan SV, Avakyan KV, Amiryan AG, Aslanidi IP, Mukhortova OV. The role of positron emission tomography/computed tomography in the diagnosis of metastatic uveal melanoma. Russian Ophthalmological Journal. 2017;10(2):54-61. (In Russ.). https://doi.org/10.21516/2072-0076-2017-10-2-54-61
  11. Avakyan KV, Saakyan SV, Amiryan AG, Aslanidi IP, Mukhortova OV. Possibilities of modern instrumental research methods in visualization of metastatic foci in patients with uveal melanoma. Golova i Sheya. Head and Neck. Russian Journal. 2017;(3):11-16. (In Russ.).
  12. Avakyan KV, Saakyan SV, Amiryan AG, Aslanidi IP, Mukhortova OV. The role of modern research methods in the early diagnosis of metastases in patients with uveal melanoma. Russian Electronic Journal of Radiation Diagnostics. 2016;6(4):8-18. (In Russ.). https://doi.org/10.21569/2222-7415-2016-6-4-8-18
  13. Neroev VV, Saakyan SV, Amiryan AG, Valskii VV. Radiation complications after brachytherapy for uveal melanoma, their relationship with clinical, sonographic, hemodynamic characteristics and the degree of tumor resorption. Russian Electronic Journal of Radiation Diagnostics. 2018;8(2):8-23. (In Russ.). https://doi.org/10.21569/2222-7415-2018-8-2-8-23
  14. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2009;27(1):122-133.  https://doi.org/10.1016/j.clindermatol.2008.09.010
  15. Gavrilova TV, Chereshneva MV, Baktikova LI. Survival of patients after removal of the eyeball for uveal melanoma in the Perm region. Ophthalmology. 2017;14(2):170-174. (In Russ.). https://doi.org/10.18008/1816-5095-2017-2-170-174
  16. Ulmer A, Beutel J, Süsskind D, Hilgers RD, Ziemssen F, Lüke M, Röcken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res. 2008;14(14):4469-4474. https://doi.org/10.1158/1078-0432.CCR-08-0012
  17. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885. https://doi.org/10.1016/j.ophtha.2011.01.040
  18. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al. Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123(12):1639-1643. https://doi.org/10.1001/archopht.123.12.1639
  19. Kazantsev AN, Abdullaev IA, Danilchuk LB, Shramko VA, Korotkikh AV, Chernykh KP, Bagdavadze G, Zharova AS, Kharchilava EU, Lider R, Kazantseva Y, Zakeryayev AB, et al. CAROTIDSCORE.RU-The first Russian computer program for risk stratification of postoperative complications of carotid endarterectomy. Vascular. 2024;32(1):132-142.  https://doi.org/10.1177/17085381221124709
  20. Saakyan SV, Panteleeva OG, Shirin TV. Features of metastatic lesions and survival of patients with uveal melanoma depending on the method of treatment. Russian Ophthalmological Journal. 2012;5(2):55-58. (In Russ.).
  21. Chew AL, Spilsbury K, Isaacs TW. Survival from uveal melanoma in Western Australia 1981-2005. Clin Exp Ophthalmol. 2015;43(5):422-428.  https://doi.org/10.1111/ceo.12490
  22. Saakyan SV, Amiryan AG, Tsygankov AYu, Sklyarova NV, Zaletaev DV. Clinical, pathomorphological and molecular genetic features of uveal melanoma with a high risk of metastasis. Russian Ophthalmological Journal. 2015;8(2):47-52. (In Russ.).
  23. Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279-289.  https://doi.org/10.2147/OPTH.S89591
  24. Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018757175. https://doi.org/10.1177/1758834018757175
  25. van den Bosch T, van Beek JG, Vaarwater J, Verdijk RM, Naus NC, Paridaens D, de Klein A, Kiliç E. Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012;53(6):2668-2674. https://doi.org/10.1167/iovs.11-8697
  26. Cassoux N, Rodrigues MJ, Plancher C, Asselain B, Levy-Gabriel C, Lumbroso-Le Rouic L, Piperno-Neumann S, Dendale R, Sastre X, Desjardins L, et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol. 2014;98(6):769-774.  https://doi.org/10.1136/bjophthalmol-2013-303867
  27. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596-1603. https://doi.org/10.1016/j.ophtha.2012.02.017
  28. Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22(5):1234-1242. https://doi.org/10.1158/1078-0432.CCR-15-2071
  29. Kosyrev VYu, Martynkov DV, Virshke ER, Buidenok YuV, Nazarova VV. The effectiveness of transarterial chemoembolization in liver metastases of uveal melanoma. Practical Oncology. 2020;21(4):284-295. (In Russ.). https://doi.org/10.31917/2104284
  30. Unguryan VM, Kazantsev AN, Korotkikh AV, Belov YuV, Ivanov SA, Kaprin AD. Isolated liver chemo perfusion for hepatic metastases from uveal melanoma: a report of 38 cases. Indian J Thorac Cardiovasc Surg. 2023. https://doi.org/10.1007/s12055-023-01620-6
  31. Kaprin AD, Ivanov SA, Unguryan VM, Kazantsev AN, Belov YuV. A method of isolated liver perfusion with melphalan followed by pembrolizumab in the treatment of unresectable uveal melanoma metastases limited to the liver. Surgery. Journal named after N.I. Pirogov. 2023;(7):94-99. (In Russ.). https://doi.org/10.17116/hirurgia202307194
  32. Dolgushin BI, Kosyrev VYu, Virshke ER, Martynkov DV. Possibilities of using transarterial chemoembolization in patients with choroidal melanoma metastases in the liver. Journal of Oncology: Radiation Diagnostics, Radiation Therapy. 2018;1(1):45-52. (In Russ.). https://doi.org/10.37174/2587-7593-2018-1-1-45-52
  33. Sinyavskii OA, Astapenko AM, Toyalinova TM, Solonina SN, Rodina LN, Troyanovskii RL, Ivanov PI, Golovin AS, Tibilov AV, Zubatkina IS, Mednikov SN. Organ-sparing treatment of uveal melanomas with gamma knife as monotherapy and in combination with endoresection and block excision. Scientific Bulletin of Public Health of the Kuban. 2017;(1):37-47. (In Russ.).
  34. Dolgushin BI, Kosyrev VYu, Martynkov DV, Demidov LV, Shishkina NA, Utyashev IA, Nazarova VV. Transarterial chemoembolization in liver metastases of uveal melanoma. Bulletin of Roentgenology and Radiology. 2016;97(4):215-223. (In Russ.). https://doi.org/10.20862/0042-4676-2016-97-4-215-223
  35. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010;37(2):127-138.  https://doi.org/10.1053/j.seminoncol.2010.03.014
  36. Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012;38(5):549-553.  https://doi.org/10.1016/j.ctrv.2012.01.002
  37. Unguryan VM, Kazantsev AN, Belov YuV. Selection of vascular access for isolated liver chemoperfusion for liver metastases. Place of artificial circulation. Literature review. Russian Journal of Cardiology. 2023;28(6):101-107. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5393
  38. Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: recent failures and new perspectives. Cancers (Basel). 2019;11(6):846.  https://doi.org/10.3390/cancers11060846
  39. Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, et al.; United Kingdom Uveal Melanoma Guideline Development Working Group. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2404-2412. https://doi.org/10.1016/j.ejca.2015.07.013
  40. Kaprin AD, Ivanov SA, Petrov LO, Kazantsev AN, Unguryan VM. A method of isolated endovascular chemoperfusion of the liver for metastases of uveal melanoma to the liver. Surgery. Journal named after N.I. Pirogov. 2023;(8):75-80. (In Russ.). https://doi.org/10.17116/hirurgia202308175
  41. Unguryan VM, Kazantsev AN, Korotkikh AV, Ivanov SA, Belov YuV, Kaprin AD. Personalized choice of vascular access for isolated liver chemoperfusion: analysis of complications risk stratification programs. Russian Journal of Cardiology. 2023;28(7):84-94. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5486
  42. Unguryan VM, Kazantsev AN, Petrov LO, Belov YuV., Kaprin AD. Assessment of intraoperative complications during isolated liver chemoperfusion. Oncology Issues. 2023;69(3S):111-112. (In Russ.).
  43. Unguryan VM, Kazantsev AN, Korotkikh AV, Ivanov SA, Belov YuV, Kaprin AD. Isolated liver chemoperfusion for uveal melanoma metastases: in-hospital results. Circulatory Pathology and Cardiac Surgery. 2023;27(3):74-82. (In Russ.). https://doi.org/10.21688/1681-3472-2023-3-74-82
  44. Kaprin AD, Unguryan VM, Kazantsev AN, Ivanov SA, Petrov LO, Kruglov EA, Pobedintseva YuA, Filimonov EV, Azarova EA, Belov YuV. Surgical treatment of uveal melanoma metastases in the liver. Oncology. Journal named after P.A. Herzen. 2023;12(5):52-57. (In Russ.). https://doi.org/10.17116/onkolog20231205152
  45. Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564. https://doi.org/10.1371/journal.pone.0118564
  46. Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017;82:56-65.  https://doi.org/10.1016/j.ejca.2017.05.038
  47. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344-3353. https://doi.org/10.1002/cncr.30258
  48. Sato T, Nathan PD, Hernandez-Aya L, Sacco JJ, Orloff MM, Visich J, Little N, Hulstine AM, Coughlin CM, Carvajal RD. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings. J Clin Oncol. 2018;36(15 suppl.):9521. https://doi.org/10.1200/JCO.2018.36.15_suppl.9521
  49. Carvajal RD, Sacco J, Nathan P, Orloff M, Little N, McAlpine C, Krige D, Hassan N, HulstineAM, Coughlin C, et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma. Invest Ophthalmol Vis Sci. 2018;59:3622.
  50. Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792-802.  https://doi.org/10.1016/S1470-2045(17)30251-6
  51. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311(23):2397-2405. https://doi.org/10.1001/jama.2014.6096
  52. Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a Phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36(12):1232-1239. https://doi.org/10.1200/JCO.2017.74.1090
  53. Piperno-Neumann S, Kapiteijn E, Larkin J. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. J Clin Oncol. 2014;32(15_suppl.):9030. https://doi.org/10.1200/jco.2014.32.15_suppl.9030
  54. Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses. 2015;7(11):6009-6042. https://doi.org/10.3390/v7112923
  55. García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30(3):352-364.  https://doi.org/10.1089/hum.2018.107
  56. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665-1670. https://doi.org/10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j
  57. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260(7):974-976. 
  58. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, Gholami A. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133(3):177-184.  https://doi.org/10.1007/s00432-006-0155-z
  59. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33(5):474-480.  https://doi.org/10.1097/COC.0b013e3181b4b065
  60. Huppert PE, Fierlbeck G, Pereira P, Schanz S, Duda SH, Wietholtz H, Rozeik C, Claussen CD. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74(3):e38-44.  https://doi.org/10.1016/j.ejrad.2009.03.064
  61. Gonsalves CF, Adamo RD, Eschelman DJ. Locoregional therapies for the treatment of uveal melanoma hepatic metastases. Semin Intervent Radiol. 2020;37(5):508-517.  https://doi.org/10.1055/s-0040-1720948
  62. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425-434.  https://doi.org/10.3348/kjr.2009.10.5.425
  63. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15(4):297-304.  https://doi.org/10.1097/00008390-200508000-00011
  64. Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T. Uveal melanoma metastatic to the liver: chemoembolization with 1,3-Bis-(2-Chloroethyl)-1-nitrosourea. AJR Am J Roentgenol. 2015;205(2):429-433.  https://doi.org/10.2214/AJR.14.14001
  65. Carling U, Dorenberg EJ, Haugvik SP, Eide NA, Berntzen DT, Edwin B, Dueland S, Røsok B. Transarterial chemoembolization of liver metastases from uveal melanoma using irinotecan-loaded beads: treatment response and complications. Cardiovasc Intervent Radiol. 2015;38(6):1532-1541. https://doi.org/10.1007/s00270-015-1093-4
  66. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26(33):5436-5442. https://doi.org/10.1200/JCO.2008.16.0705
  67. Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, Pearce N, Takhar A, Gupta S, Hardman D, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170-1178. https://doi.org/10.1002/jso.24956
  68. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009;252(1):290-298.  https://doi.org/10.1148/radiol.2521081252
  69. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26(4):523-532.e2.  https://doi.org/10.1016/j.jvir.2014.11.037
  70. Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, Beny A, Dezarn WA. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27(6):682-690.  https://doi.org/10.1080/07357900802620893
  71. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011;196(2):468-473.  https://doi.org/10.2214/AJR.10.4881
  72. Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol. 2013;36(1):158-165.  https://doi.org/10.1007/s00270-012-0373-5
  73. Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Bar-Ad V, Dicker A, Doyle L, Li J, et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. Am J Clin Oncol. 2016;39(2):189-195.  https://doi.org/10.1097/COC.0000000000000033
  74. Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I, Sato T. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology. 2019;293(1):223-231.  https://doi.org/10.1148/radiol.2019190199
  75. Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89(7):1561-1568. https://doi.org/10.1002/1097-0142(20001001)89:7<1561::aid-cncr21>3.0.co;2-r
  76. Akyuz M, Yazici P, Dural C, Yigitbas H, Okoh A, Bucak E, McNamara M, Singh A, Berber E. Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc. 2016;30(6):2567-2571. https://doi.org/10.1007/s00464-015-4527-9
  77. Mariani P, Almubarak MM, Kollen M, Wagner M, Plancher C, Audollent R, Piperno-Neumann S, Cassoux N, Servois V. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016;42(5):706-712.  https://doi.org/10.1016/j.ejso.2016.02.019
  78. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35(11):1192-1197. https://doi.org/10.1016/j.ejso.2009.02.016
  79. Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J. 2010;16(2):132-141.  https://doi.org/10.1097/PPO.0b013e3181db9c0a
  80. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9(17):6343-6349.
  81. Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, Pearce N, Takhar A, Gupta S, Hardman D, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170-1178. https://doi.org/10.1002/jso.24956
  82. Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A, Eigentler T, Syha R, Grözinger G. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19(1):31.  https://doi.org/10.1186/s40644-019-0218-4
  83. Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22(4):497-505.  https://doi.org/10.1016/j.hpb.2019.11.002
  84. Yang XY, Xie F, Tao R, Li AJ, Wu MC. Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis. Hepatobiliary Pancreat Dis Int. 2013;12(6):602-606.  https://doi.org/10.1016/s1499-3872(13)60095-8
  85. Ben-Shabat I, Belgrano V, Hansson C, Olofsson Bagge R. The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases. Int J Hyperthermia. 2017;33(4):483-488.  https://doi.org/10.1080/02656736.2017.1286046
  86. Alexander HR Jr, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am. 1998;4(1):2-11. 
  87. Ben-Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, Olofsson Bagge R. Long-term follow-up evaluation of 68 patients with uveal melanoma liver metastases treated with isolated hepatic perfusion. Ann Surg Oncol. 2016;23(4):1327-1334. https://doi.org/10.1245/s10434-015-4982-5
  88. Vogl TJ, Koch SA, Lotz G, Gebauer B, Willinek W, Engelke C, Brüning R, Zeile M, Wacker F, Vogel A, et al. Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol. 2017;40(6):864-872.  https://doi.org/10.1007/s00270-017-1588-2
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.